This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

FDA Approves GE Healthcare's AdreView™ (Iobenguane I 123 Injection) For Cardiac Risk Evaluation In Heart Failure Patients

For our latest news, please visit http://newsroom.gehealthcare.com

_________________________

1 Jacobson AF, Senior R, Cerqueira MD, et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure: results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) Study. J Am Coll Cardiol. 2010;55:2212-2221

2 AdreView Prescribing Information, GE Healthcare. 2013.

3 Leimbach WN Jr., Wallin BG, Victor RG, Aylward PE, Sundlof G, Mark AL. Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. Circulation 1986;73:913–9.

4 Brunner-La Rocca HP, Esler MD, Jennings GL, Kay DM. Effect of cardiac nervous activity on mode of death in congestive heart failure. Eur Heart J 2001;22:1136–43.

5 Eisenhafer G, Friberg P, Rundqvist B, et al. Cardiac sympathetic nerve function in congestive heart failure. Circulation. 1996;93:1667-1676.

6 The American Heritage Medical Dictionary. http://medical-dictionary.thefreedictionary.com/mediastinum. Accessed March 2013.

7 Hall MJ, Levant S, DeFrances C. Hospitalization for Congestive Heart Failure: United States, 2000-2010. US Department of Health and Human Services. Centers for Disease Control and Prevention. 2012.

8 Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics—2013 update: a report from the American Heart Association. Circulation.2013;127:e6-e245.

9 National Heart, Lung, and Blood Institute. Congestive Heart Failure: A New Epidemic in the United States. Data Fact Sheet. September 1996

 




Copyright Business Wire 2010
3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,097.62 +62.69 0.35%
S&P 500 2,100.40 +19.22 0.92%
NASDAQ 4,994.6020 +62.7870 1.27%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs